Literature DB >> 28270299

Research Advances in Resistance to Platinum-based Chemotherapy in Lung Cancer.

Yajuan Zhang1, Jianpeng Zhang2.   

Abstract

Platinum-based chemotherapy is the the cornerstone of treatment of many cancers. Combinations of platinum drugs with other agents are still the mainstream therapies for non-small cell lung cancer,showing significant effectiveness in an early phase. Along with the treatment,the tumor cells can become resistant to chemotherapy drugs,which affect the efficacy and prognosis. The mechanisms of drug resistance are complicated,including abnormal expressions of membrane proteins,enhanced DNA repair functions,abnormal regulation mechanisms of apoptosis,and enhanced cellular detoxification function. In this article we summarize some of the main mechanisms of platinum resistance in lung cancer cells,with an attempt to identify new potential target analogues or inhibitors and improve the efficacies of the combined use of platinum-based drugs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28270299     DOI: 10.3881/j.issn.1000-503X.2017.01.025

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  2 in total

Review 1.  Kangai Injection Combined with Platinum-based Chemotherapy for the Treatment of Stage III/IV Non-Small Cell Lung Cancer: A Meta-analysis and Systematic Review of 35 Randomized Controlled Trials.

Authors:  Hongxiao Li; Yuejin Ji; Shiping Zhang; Zishan Gao; Cheng Hu; Rilei Jiang; Meijuan Chen; Guochun Li; Xu Zhang
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

2.  Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer.

Authors:  Huawei Lin; Jing Chang; Jun Li
Journal:  Iran J Public Health       Date:  2020-10       Impact factor: 1.429

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.